公开(公告)号：US20210213039A1

公开(公告)日：2021-07-15

申请号：US17218814

申请日：2021-03-31

申请人： Bitop AG

发明人： Andreas Bilstein ,  Olaf Scherner ,  Georg Lentzen

IPC分类号： A61K31/7032 ,  A61L26/00 ,  A61K31/505 ,  A61K45/06 ,  C07D239/06 ,  C07H15/04

摘要： The invention relates to a composition containing as active agent ectoine, hydroxyectoine, glucosylglycerol and/or salts, esters or amides of these compounds for promoting the regeneration of injured body tissue. The invention has special significance for the treatment of chronic wounds or ulcers.

公开(公告)号：US11052123B2

公开(公告)日：2021-07-06

申请号：US16499396

申请日：2018-03-29

申请人： ISANATUR SPAIN S.L.

发明人： Nuria Mateo Ansón

IPC分类号： A61K36/63 ,  A23L33/105 ,  A23L5/30 ,  A23D9/02 ,  A61K31/01 ,  A61K31/047 ,  A61K31/05 ,  A61K31/222 ,  A61K31/355 ,  A61K31/7032 ,  A61K31/7048 ,  B01D11/02 ,  C11B1/04 ,  C11B1/10

摘要： A method comprising the stages of: olive input, separation of the stone from the olive skin and pulp, with the removal of the whole stone; electric pulsing of the olive paste generated in the previous stage, process of dehydration of the pulsed olive paste up to a humidity of less than 30% in a continuous vacuum drying machine and subsequent separation of the oil by centrifugation of the olive oil, followed by dehydration of the degreased pulp up to a humidity of less than 10%; and lastly, application of supercritical fluids (CO2 with or without modifier) to the degreased and dehydrated pulp, under agitation, pressure, temperature and time conditions, obtaining olive extracts and olive flour. The generation of waste, consumption of water, use of highly toxic solvents and loss of the sensory quality of the oil is avoided, the yields improved and the necessary times reduced.

公开(公告)号：US20210169909A1

公开(公告)日：2021-06-10

申请号：US17182098

申请日：2021-02-22

申请人： GRI BIO, INC.

发明人： Vipin Kumar Chaturvedi

IPC分类号： A61K31/7032 ,  A61K45/06 ,  A61K31/07 ,  A61K31/203 ,  A61K31/192 ,  A61K31/4436

摘要： The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

公开(公告)号：US20210121538A1

公开(公告)日：2021-04-29

申请号：US17072005

申请日：2020-10-15

申请人： Nobelbiotix Research Institute Limited

发明人： Winston Kuang Hui Man A Hing

IPC分类号： A61K38/44 ,  A61K47/46 ,  A61K47/36 ,  A61K47/02 ,  A61K47/06 ,  A61K47/20 ,  A61K47/32 ,  A61K47/44 ,  A61K47/28 ,  A61K47/18 ,  A61K45/06 ,  A61K31/375 ,  A61K31/194 ,  A61K31/122 ,  A61K31/015 ,  A61K31/355 ,  A61K31/353 ,  A61K31/593 ,  A61K31/352 ,  A61K31/336 ,  A61K31/4415 ,  A61K31/525 ,  A61K31/714 ,  A61K31/455 ,  A61K31/198 ,  A61K31/131 ,  A61K31/7076 ,  A61K31/664 ,  A61K31/10 ,  A61K38/05 ,  A61K38/06 ,  A61K31/7032 ,  A61K31/7084 ,  A61K35/76 ,  A61K35/748 ,  A61K36/05 ,  A61K36/06 ,  A61K35/74

摘要： A micro-environment bioreaction aggregate (“MEBA”) is formed by combining a non-digestible carrier system with redox potential (“Eh”) regulating compounds. The bioreaction aggregate is introduced into a microbial environment, such as soil, hydroponic systems, or gastrointestinal tracts of animals or humans. Said MEBA regulates the Eh of the microbial microhabitat and its surroundings, thereby providing numerous benefits towards the prevention and treatment of diseases and dysbiosis.

公开(公告)号：US20210052677A1

公开(公告)日：2021-02-25

申请号：US16947866

申请日：2020-08-21

申请人： Wake Forest University Health Sciences

发明人： HARIOM YADAV ,  SHAOHUA WANG ,  RAVINDER NAGPAL

IPC分类号： A61K35/747 ,  A61K9/00 ,  A61K9/19 ,  A61P1/00 ,  A61P29/00 ,  A61K31/7032 ,  A23L33/135 ,  A23L33/00

摘要： Provided is a composition comprising an isolated Lactobacillus paracasei D3.5 strain or cellular components thereof. In some embodiments, the composition is provided in a pharmaceutically acceptable carrier, which may be a food product, tablet or capsule suitable for enteral administration, etc. Also provided is a composition comprising lipoteichoic acid isolated from Lactobacillus paracasei D3.5 strain, which may be provided in a pharmaceutically acceptable carrier.

公开(公告)号：US20210023109A1

公开(公告)日：2021-01-28

申请号：US17037079

申请日：2020-09-29

申请人： Northwestern University

发明人： Stephen F. Murphy ,  Praveen Thumbikat ,  Anthony Schaeffer

IPC分类号： A61K31/7032 ,  A61K35/741 ,  A61P29/00 ,  A61P19/02 ,  A61K9/00 ,  A61P37/06

摘要： Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune- (e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

公开(公告)号：US20200330380A1

公开(公告)日：2020-10-22

申请号：US16851177

申请日：2020-04-17

申请人： DePuy Synthes Products, Inc.

发明人： Charles Florek ,  David A. Armbruster ,  Sean Hamilton Kerr ,  Sanjay Jain ,  Junior Julien ,  Malavosklish Bikram-Liles

IPC分类号： A61K9/06 ,  A61K47/14 ,  A61K47/12 ,  A61K47/10 ,  A61K47/26 ,  A61K9/14 ,  A61K31/7036 ,  A61K38/14 ,  A61K31/407 ,  A61K31/7032 ,  A61K9/00

摘要： The present disclosure is directed to an organogel drug depot for use in delivering an active agent to a surgical site, such as an implant site, for instance an orthopedic implant site. The present disclosure is also directed to an organogel drug depot for use in a non-sterile environment and application to a non-sterile open wound site. In a further embodiment, there is disclosed a system for preparing an organogel drug depot including an organogel matrix comprising an organogelator and a biocompatible organic solvent, an active agent comprising solid particles, a container including at least one wall having an outer surface and defining a volume capable of containing the organogel matrix and active agent solid particles, and a heating component configured to contact the outer surface and supply an amount of heat to the container.

公开(公告)号：US10772902B2

公开(公告)日：2020-09-15

申请号：US16074554

申请日：2017-01-27

申请人： OCELAND BIOLOGICALS LIMITED

发明人： Balakrishnan Prithiviraj ,  Garima Kulshrestha

IPC分类号： A61K31/7032 ,  C07H15/04 ,  A61K31/185 ,  A61K45/06 ,  A61P31/04 ,  A61K31/65

摘要： The present disclosure provides: floridoside or isethionic acid for use as an antibiotic potentiator; floridoside or isethionic acid in a combination therapy with an antibiotic compound; as well as methods of potentiating the antibiotic activity of an antibiotic compound, where the method comprises administering floridoside or isethionic acid to an animal or plant.

公开(公告)号：US10751342B2

公开(公告)日：2020-08-25

申请号：US16748142

申请日：2020-01-21

申请人： Pharmacyclics LLC

发明人： Joseph J. Buggy ,  Gwen Fyfe ,  Lee Honigberg ,  David J. Loury

IPC分类号： A61K31/519 ,  A61K9/48 ,  A61K9/00 ,  A61K39/395 ,  A61K31/664 ,  A61K31/437 ,  A61K31/337 ,  C07D487/04 ,  A61K31/7032 ,  A61K31/4745 ,  A61K31/4184 ,  A61K45/06 ,  A61K31/7076 ,  A61K31/704 ,  A61K31/69 ,  A61K31/675 ,  A61K31/606 ,  A61K31/573 ,  A61K31/475 ,  A61K31/454 ,  A61K31/436 ,  A61K31/195 ,  A61K47/26 ,  A61K47/38 ,  A61K47/14 ,  A61K47/36 ,  A61K47/20 ,  A61K47/10 ,  A61K47/12 ,  A61K9/06

摘要： Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：US20200230163A1

公开(公告)日：2020-07-23

申请号：US16647379

申请日：2018-09-13

申请人： ABIVAX

发明人： Sandrine CRABE ,  Didier SCHERRER ,  Hartmut EHRLICH ,  Philippe POULETTY

IPC分类号： A61K31/7032 ,  A61P35/00

摘要： The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.